News & Events
The Drugs Technical Advisory Board has examined the issue of suspension of manufacture and sale of Pioglitazone on 19th July 2013 & has recommended that the Suspension of the drug should be revoked and allowed to be marketed subject to certain conditions the manufacturers shall mention on their package insert and promotional literature of the drug. Based on DTAB report Ministry of health & family welfare & Central Government revokes the notification G.S.R.379(E) dated 18th June 2013.
A new study presented at EULAR 2013,the Annual Congress of the European League Against Rheumatism shows that one in eight patients at risk of developing a serious adverse drug event (ADE) is taking over the counter (OTC) non-steroidal anti-inflammatory drugs (NSAIDs), often to treat a musculoskeletal complaint Possible serious ADEs include gastrointestinal bleeding, peptic ulceration, high blood pressureand worsening heart failure.
Researchers reported at the American Heart Association's 50th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, that the increase in sugar consumption has led to more diabetes and heart disease over the past decade.
People taking statin drugs to lower their cholesterol may slightly increase their risk for muscle and joint diseases as well as strains and sprains, a new study suggests.The results were published online June 3 in the journal JAMA Internal Medicine.

Slideshow Image 1
Slideshow Image 2
Slideshow Image 1
Slideshow Image 2
Slideshow Image 1
   Telmisartan Tablets IP

  ONTEL™ 20mg: Each uncoated tablet contains: Telmisartan IP 20 mg,
ONTEL™ 40mg: Each uncoated tablet contains: Telmisartan IP 40 mg
  Treatment of hypertension.  
The usual starting dose of Ontel is 40 mg once a day. Blood pressure response is dose-related over the range of 20-40 mg. Ontel may be administered with or without food.
In patients with known hypersensitivity (e.g., anaphylaxis or angioedema) to telmisartan or any other component of this product.
Can cause fetal/neonatal morbidity and mortality when administered to pregnant women. Symptomatic hypotension may occur after initiation of therapy with telmisartan. Either correct this condition prior to administration of telmisartan or start treatment under medical supervision with reduced dose. Hyperkalemia may occur in patients on ARBs (angiotensin-renin blockers), particularly in patients with advanced renal impairment, heart failure, on renal replacement therapy, or on potassium supplements, potassiumsparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levels. Reduced clearance in case of impaired hepatic function – initiate telmisartan at low dose and titrate slowly. Changes in renal function can be anticipated in susceptible individuals. Dual blockade of the renin-angiotensin-aldosterone system should include close monitoring of renal function. Concomitant use of telmisartan and ramipril is not recommended.
  Back to Products  



Home | About Us | Products | Enquiry | Contact Us | Order | Carrer
  All Rights Reserved By : Cadell Health care Pvt Ltd. Designed & Maintained By : Daffodil Design & Prints